Heparin-induced platelet dysfunction and cardiopulmonary bypass

Elijah W. Muriithi, Philip R. Belcher, Stephen P. Day, Valentine C. Menys, David J. Wheatley

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Cardiopulmonary bypass is associated with impaired platelet macroaggregation. Heparin contributes to platelet dysfunction before extracorporeal circulation. In vitro heparinization of whole blood does not impair macroaggregation. Heparin releases several endothelial proteins; thus heparin may inhibit macroaggregation indirectly.

METHODS: Patients undergoing operations using cardiopulmonary bypass and ABO blood group compatible volunteers were studied. Whole blood impedance aggregometry assessed macroaggregation in response to collagen (0.6 microg ml(-1)) in blood diluted either with normal saline or with platelet poor plasma, obtained from patients at different stages of cardiopulmonary bypass.

RESULTS: Before heparinization, blood diluted with its own platelet poor plasma recorded an impedance change of 13.0 (4.7 to 15.6) Ohms. Platelet poor plasma obtained after heparinization or during extracorporeal circulation reduced this response to 3.7 (1.1 to 8.4) and 2.0 (1.1 to 3.3) Ohms, respectively (both p < 0.0001 versus pre-heparin; n = 13). Macroaggregation in blood from volunteers was similarly inhibited by patients' platelet poor plasma (n = 30). The macroaggregatory response in blood sampled after heparinization for cardiopulmonary bypass, decreased gradually from 11.4 (8.2 to 15.9) Ohms immediately after sampling to 1.7 (1.4 to 4.1) Ohms 2 hours later (p < 0.0001; n = 11).

CONCLUSIONS: In vivo heparinization induces plasma changes that inhibit platelet macroaggregation. This is an indirect, delayed inhibition that is transferable in vitro to normal platelets.

Original languageEnglish
Pages (from-to)1827-1832
Number of pages6
JournalThe Annals of Thoracic Surgery
Volume69
Issue number6
DOIs
Publication statusPublished - Jun 2000
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Heparin
Blood Platelets
Extracorporeal Circulation
Electric Impedance
Volunteers
Blood Group Antigens
Collagen
Proteins

Keywords

  • Blood Platelet Disorders
  • Blood Platelets
  • Cardiopulmonary Bypass
  • Dose-Response Relationship, Drug
  • Hemodilution
  • Heparin
  • Humans
  • Platelet Aggregation
  • Clinical Trial
  • Comparative Study
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Muriithi, Elijah W. ; Belcher, Philip R. ; Day, Stephen P. ; Menys, Valentine C. ; Wheatley, David J. / Heparin-induced platelet dysfunction and cardiopulmonary bypass. In: The Annals of Thoracic Surgery. 2000 ; Vol. 69, No. 6. pp. 1827-1832.
@article{bc2a0099f032479182e0e7abde291b8c,
title = "Heparin-induced platelet dysfunction and cardiopulmonary bypass",
abstract = "BACKGROUND: Cardiopulmonary bypass is associated with impaired platelet macroaggregation. Heparin contributes to platelet dysfunction before extracorporeal circulation. In vitro heparinization of whole blood does not impair macroaggregation. Heparin releases several endothelial proteins; thus heparin may inhibit macroaggregation indirectly.METHODS: Patients undergoing operations using cardiopulmonary bypass and ABO blood group compatible volunteers were studied. Whole blood impedance aggregometry assessed macroaggregation in response to collagen (0.6 microg ml(-1)) in blood diluted either with normal saline or with platelet poor plasma, obtained from patients at different stages of cardiopulmonary bypass.RESULTS: Before heparinization, blood diluted with its own platelet poor plasma recorded an impedance change of 13.0 (4.7 to 15.6) Ohms. Platelet poor plasma obtained after heparinization or during extracorporeal circulation reduced this response to 3.7 (1.1 to 8.4) and 2.0 (1.1 to 3.3) Ohms, respectively (both p < 0.0001 versus pre-heparin; n = 13). Macroaggregation in blood from volunteers was similarly inhibited by patients' platelet poor plasma (n = 30). The macroaggregatory response in blood sampled after heparinization for cardiopulmonary bypass, decreased gradually from 11.4 (8.2 to 15.9) Ohms immediately after sampling to 1.7 (1.4 to 4.1) Ohms 2 hours later (p < 0.0001; n = 11).CONCLUSIONS: In vivo heparinization induces plasma changes that inhibit platelet macroaggregation. This is an indirect, delayed inhibition that is transferable in vitro to normal platelets.",
keywords = "Blood Platelet Disorders, Blood Platelets, Cardiopulmonary Bypass, Dose-Response Relationship, Drug, Hemodilution, Heparin, Humans, Platelet Aggregation, Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't",
author = "Muriithi, {Elijah W.} and Belcher, {Philip R.} and Day, {Stephen P.} and Menys, {Valentine C.} and Wheatley, {David J.}",
year = "2000",
month = "6",
doi = "10.1016/S0003-4975(00)01299-6",
language = "English",
volume = "69",
pages = "1827--1832",
journal = "The Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

Heparin-induced platelet dysfunction and cardiopulmonary bypass. / Muriithi, Elijah W.; Belcher, Philip R.; Day, Stephen P.; Menys, Valentine C.; Wheatley, David J.

In: The Annals of Thoracic Surgery, Vol. 69, No. 6, 06.2000, p. 1827-1832.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heparin-induced platelet dysfunction and cardiopulmonary bypass

AU - Muriithi, Elijah W.

AU - Belcher, Philip R.

AU - Day, Stephen P.

AU - Menys, Valentine C.

AU - Wheatley, David J.

PY - 2000/6

Y1 - 2000/6

N2 - BACKGROUND: Cardiopulmonary bypass is associated with impaired platelet macroaggregation. Heparin contributes to platelet dysfunction before extracorporeal circulation. In vitro heparinization of whole blood does not impair macroaggregation. Heparin releases several endothelial proteins; thus heparin may inhibit macroaggregation indirectly.METHODS: Patients undergoing operations using cardiopulmonary bypass and ABO blood group compatible volunteers were studied. Whole blood impedance aggregometry assessed macroaggregation in response to collagen (0.6 microg ml(-1)) in blood diluted either with normal saline or with platelet poor plasma, obtained from patients at different stages of cardiopulmonary bypass.RESULTS: Before heparinization, blood diluted with its own platelet poor plasma recorded an impedance change of 13.0 (4.7 to 15.6) Ohms. Platelet poor plasma obtained after heparinization or during extracorporeal circulation reduced this response to 3.7 (1.1 to 8.4) and 2.0 (1.1 to 3.3) Ohms, respectively (both p < 0.0001 versus pre-heparin; n = 13). Macroaggregation in blood from volunteers was similarly inhibited by patients' platelet poor plasma (n = 30). The macroaggregatory response in blood sampled after heparinization for cardiopulmonary bypass, decreased gradually from 11.4 (8.2 to 15.9) Ohms immediately after sampling to 1.7 (1.4 to 4.1) Ohms 2 hours later (p < 0.0001; n = 11).CONCLUSIONS: In vivo heparinization induces plasma changes that inhibit platelet macroaggregation. This is an indirect, delayed inhibition that is transferable in vitro to normal platelets.

AB - BACKGROUND: Cardiopulmonary bypass is associated with impaired platelet macroaggregation. Heparin contributes to platelet dysfunction before extracorporeal circulation. In vitro heparinization of whole blood does not impair macroaggregation. Heparin releases several endothelial proteins; thus heparin may inhibit macroaggregation indirectly.METHODS: Patients undergoing operations using cardiopulmonary bypass and ABO blood group compatible volunteers were studied. Whole blood impedance aggregometry assessed macroaggregation in response to collagen (0.6 microg ml(-1)) in blood diluted either with normal saline or with platelet poor plasma, obtained from patients at different stages of cardiopulmonary bypass.RESULTS: Before heparinization, blood diluted with its own platelet poor plasma recorded an impedance change of 13.0 (4.7 to 15.6) Ohms. Platelet poor plasma obtained after heparinization or during extracorporeal circulation reduced this response to 3.7 (1.1 to 8.4) and 2.0 (1.1 to 3.3) Ohms, respectively (both p < 0.0001 versus pre-heparin; n = 13). Macroaggregation in blood from volunteers was similarly inhibited by patients' platelet poor plasma (n = 30). The macroaggregatory response in blood sampled after heparinization for cardiopulmonary bypass, decreased gradually from 11.4 (8.2 to 15.9) Ohms immediately after sampling to 1.7 (1.4 to 4.1) Ohms 2 hours later (p < 0.0001; n = 11).CONCLUSIONS: In vivo heparinization induces plasma changes that inhibit platelet macroaggregation. This is an indirect, delayed inhibition that is transferable in vitro to normal platelets.

KW - Blood Platelet Disorders

KW - Blood Platelets

KW - Cardiopulmonary Bypass

KW - Dose-Response Relationship, Drug

KW - Hemodilution

KW - Heparin

KW - Humans

KW - Platelet Aggregation

KW - Clinical Trial

KW - Comparative Study

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/S0003-4975(00)01299-6

DO - 10.1016/S0003-4975(00)01299-6

M3 - Article

VL - 69

SP - 1827

EP - 1832

JO - The Annals of Thoracic Surgery

JF - The Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -